Trials / Completed
CompletedNCT00308737
Safety of Inhaled Insulin With Type 1 and Type 2 Diabetes
Pulmonary Outcomes Within a 2-Year Period in Subjects With Diabetes Mellitus Treated With Technosphere /Insulin or Usual Antidiabetic Treatment and in Subjects Without Abnormalities in Glucose Control.
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 2,053 (actual)
- Sponsor
- Mannkind Corporation · Industry
- Sex
- All
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Accepted
Summary
Pulmonary Safety in Diabetics with T/I
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Technosphere® Insulin Inhalation Powder | Inhalation, 15U/30U |
| DRUG | Usual Care | Subjects will receive antidiabetes treatment at the discretion of their physicians |
Timeline
- Start date
- 2005-06-01
- Primary completion
- 2008-09-01
- Completion
- 2008-10-01
- First posted
- 2006-03-30
- Last updated
- 2014-10-16
- Results posted
- 2014-10-16
Locations
176 sites across 8 countries: United States, Canada, Czechia, Poland, Russia, Spain, Ukraine, United Kingdom
Source: ClinicalTrials.gov record NCT00308737. Inclusion in this directory is not an endorsement.